AstraZeneca
AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines.
Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines.
The company operates major UK sites including its global R&D headquarters at the Cambridge Biomedical Campus and a large-scale pharmaceutical manufacturing campus in Macclesfield.
AstraZeneca serves specialist and primary care physicians across global markets.
Latest News
AstraZeneca Wins FDA Accelerated Approval for Ultomiris in IgA Nephropathy
AstraZeneca has received FDA accelerated approval for Ultomiris in adults with IgA nephropathy, based on an interim analysis showing a 43.4% reduction in proteinuria versus placebo at 34 weeks. The trial continues to 106 weeks to assess whether the drug slows loss of kidney function, which would support full approval.
AstraZeneca Signs AI Drug Discovery Deal with insitro for MASH and Cardiomyopathies
AstraZeneca has signed a drug discovery collaboration with AI biotech insitro targeting MASH and cardiomyopathies, paying $40 million upfront with up to $1.46 billion in development and commercial milestones. insitro will take AstraZeneca-nominated targets through to development candidates, with AstraZeneca holding exclusive worldwide rights.